RxDoctor Payments Data

Mark Webb, MD

Internal Medicine · Scottsdale, AZNPI 1255396867

Payments from drug & device makers

$7,570in general payments, 2019–2025

Across 406 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Amgen$462
  • Novo Nordisk$402
  • GSK$392
  • Lilly USA, LLC$298
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$7,564100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,570 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$130,922
Medicare patients
409
Services billed
1,862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$49,897
JardianceEmpagliflozin41$39,510
FarxigaDapagliflozin Propanediol46$36,926
EliquisApixaban43$35,142
TrulicityDulaglutide19$20,254
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,233
GraliseGabapentin12$10,944
Pregabalin22$7,635
Diphenhydramine Hcl19$3,285
SynthroidLevothyroxine Sodium33$2,279
Celecoxib39$2,194
Atorvastatin Calcium254$2,188
Clonidine23$2,163
BreynaBudesonide/Formoterol Fumarate13$2,101
Tamsulosin Hcl125$2,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,559$50,15967 claims
Novo NordiskOzempic$402$49,89742 claims
Boehringer IngelheimJardiance$81$39,51041 claims
PfizerEliquis, Paxlovid$225$36,57172 claims
Lilly USA, LLCTrulicity$298$20,25419 claims
Almatica Pharma LLCGralise$172$10,94412 claims
AbbVieSynthroid, Armour Thyroid$1,764$3,79045 claims
IBSA Pharma Inc.Tirosint$17$1,93814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →